Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Rx Cost Controls Could Drive "Breakthrough" R&D - Rep. Stark

Executive Summary

Medicare prescription drug budgets should be designed to encourage research into "truly new products," Rep. Stark (D-Calif.) suggested in an Aug. 8 memorandum submitted to the HHS drug pricing conference in Washington, D.C.

You may also be interested in...

Rx Price Clusters Parallel Managed Care Premiums, AstraZeneca Exec Says

Deeply discounted launch prices for brand name pharmaceuticals are rare because promotional costs are high regardless of price, AstraZeneca Director of Public Policy Robert Freeman, PhD, suggested during the HHS conference on drug pricing Aug. 8 in Washington, D.C.

Medicare Rx Pricing Plans Could Lead To "Inappropriate" R&D - MedPAC

Administered pricing for a Medicare drug benefit could result in "inappropriate patterns of investment" in pharmaceutical research and development, the Medicare Payment Advisory Commission's June 1 report to Congress states.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts